|
1
|
Zarbo RJ: Salivary gland neoplasia: A
review for the practicing pathologist. Mod Pathol. 15:298–323.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheuk W and Chan JKC: Salivary Gland
TumorsFletcher CDM: Diagnostic Histopathology of Tumors. 3rd
edition. Philadelphia: Churchill Livingstone; pp. 239–326. 2007
|
|
3
|
Lingen MW: Diseases of organ systems,
salivary glandsKumar V, Abbas AK and Fausto N: Pathologic Basis of
Disease. 7th edition. Philadelphia: Elsevier Saunders; pp. 790–795.
2005
|
|
4
|
Rosai J: Major and Minor Salivary
GlandsRosai J: Surgical Pathology. 9th edition. Philadelphia:
Elsevier Mosby; pp. 873–915. 2004
|
|
5
|
Shvero A and Hadar T: Pathology of
selected tumors of salivary gland. Med Connect. 6:29–34. 2011.
|
|
6
|
Berg JM, Tymoczko JL and Stryer L: DNA
replication, recombination and repairBerg JM, Tymoczko JL and
Stryer L: Biochemistry. 5th edition. New York: W.H.Freeman &
Co; pp. 1119–1120. 2002
|
|
7
|
Turley H, Comley M, Houlbrook S, Nozaki N,
Kikuchi A, Hickson ID, Gatter K and Harris AL: The distribution and
expression of the two isophorms of DNA topoisomerase II in normal
and neoplastic human tissues. Br J Cancer. 75:1340–1346. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsiang YH, Wu HY and Liu LF:
Proliferation-dependent regulation of DNA topoisomerase II in
cultured human cells. Cancer Res. 48:3230–3235. 1988.PubMed/NCBI
|
|
9
|
Shapiro PS, Whalen AM, Tolwinski NS,
Wilsbacher J, Froelich-Ammon SJ, Garcia M, Osheroff N and Ahn NG:
Extracellular signal-regulated kinase activates topoisomerase
IIalpha through a mechanism independent of phosphorylation. Mol
Cell Biol. 19:3551–3560. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tabata M, Tabata R, Grabowski DR, Bukowski
RM, Ganapathi MK and Ganapathi R: Roles of NF-kappaB and 26 S
proteasome in apoptotic cell death induced by topoisomerase I and
II Poisons in human non-small cell lung carcinoma. J Biol Chem.
276:8029–8036. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nikolényi A, Uhercsák G, Csenki M, Hamar
S, Csörgo E, Tánczos E, Thurzó L, Brodowicz T, Wagnerova M and
Kahán Z: Tumor topoisomerase II alpha protein expression and
outcome after adjuvant dose-dense anthracycline-based chemotherapy.
Pathol Oncol Res. 18:61–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gómez HL, Pinto JA, Olivera M, Vidaurre T,
Doimi FD, Vigil CE, Velarde RG, Abugattas JE, Alarcón E and
Vallejos CS: Topoisomerase II-α as a predictive factor of response
to therapy with anthracyclines in locally advanced breast cancer.
Breast. 20:39–45. 2001. View Article : Google Scholar
|
|
13
|
Bartlett JM, Munro AF, Dunn JA, McConkey
C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW,
et al: Predictive markers of anthracycline benefit: A prospectively
planned analysis of the UK national epirubicin adjuvant trial
(NEAT/BR9601). Lancet Oncol. 11:266–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schaeffer EM, Guzzo TJ, Furge KA, Netto G,
Westphal M, Dykema K, Yang X, Zhou M, Teh BT and Pavlovich CP:
Renal medullary carcinoma: Molecular, pathological and clinical
evidence for treatment with topoisomerase-inhibiting therapy. BJU
Int. 106:62–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferrandina G, Petrillo M, Carbone A,
Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A
and Scambia G: Prognostic role of topoisomerase-IIalpha in advanced
ovarian cancer patients. Br J Cancer. 98:1910–1915. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirabayashi S: Immunohistochemical
detection of DNA topoisomerase type II alpha and Ki-67 in adenoid
cystic carcinoma and pleomorphic adenoma of the salivary gland. J
Oral Pathol Med. 28:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maruya S, Shirasaki T, Nagaki T, Kakehata
S, Kurotaki H, Mizukami H and Shinkawa H: Differential expression
of topoisomerase IIalpha protein in salivary gland carcinomas:
Histogenetic and prognostic implications. BMC Cancer. 9:722009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen CC, Gau JP, You JY, Lee KD, Yu YB, Lu
CH, Lin JT, Lan C, Lo WH, Liu JM and Yang CF: Prognostic
significance of beta-catenin and topoisomerase IIalpha in de novo
acute myeloid leukemia. Am J Hematol. 84:87–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doussis-Anagnostopoulou IA,
Vassilakopoulos TP, Thymara I, Korkolopoulou P, Angelopoulou MK,
Siakantaris MP, Kokoris SI, Dimitriadou EM, Kalpadakis C,
Matzouranis M, et al: Topoisomerase IIalpha expression as an
independent prognostic factor in Hodgkin's lymphoma. Clin Cancer
Res. 14:1759–1766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coss A, Tosetto M, Fox EJ, Sapetto-Rebow
B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP,
Sheahan K, et al: Increased topoisomerase IIalpha expression in
colorectal cancer is associated with advanced disease and
chemotherapeutic resistance via inhibition of apoptosis. Cancer
Lett. 276:228–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY,
Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression
in hepatocellular carcinoma correlates with early age onset,
shorter patients survival and chemoresistance. Int J Cancer.
124:644–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Washiro M, Ohtsuka M, Kimura F, Shimizu H,
Yoshidome H, Sugimoto T, Seki N and Miyazaki M: Upregulation of
topoisomerase IIalpha expression in advanced gallbladder carcinoma:
A potential chemotherapeutic target. J Cancer Res Clin Oncol.
134:793–801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hughes C, Murphy A, Martin C, Fox E, Ring
M, Sheils O, Loftus B and O'Leary J: Topoisomerase II-alpha
expression increases with increasing Gleason score and with hormone
insensitivity in prostate carcinoma. J Clin Pathol. 59:721–724.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dekel Y, Frede T, Kugel V, Neumann G,
Rassweiler J and Koren R: Human DNA topoisomerase II-alpha
expression in laparoscopically treated renal cell carcinoma. Oncol
Rep. 14:271–274. 2005.PubMed/NCBI
|
|
25
|
Rath-Wolfson L, Purim O, Ram E,
Morgenstern S, Koren R and Brenner B: Expression of estrogen
receptor β1 in colorectal cancer: Correlation with
clinicopathological variables. Oncol Rep. 27:2017–2022.
2012.PubMed/NCBI
|
|
26
|
Ohtaké S, Cheng J, Ida H, Suzuki M,
Ohshiro K, Zhang W and Saku T: Precancerous foci in pleomorphic
adenoma of the salivary gland: Recognition of focal carcinoma and
atypical tumor cells by P53 immunohistochemistry. J Oral Pathol
Med. 31:590–597. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen LH, Black MJ, Hier M, Chauvin P and
Rochon L: HER2/neu and Ki-67 as prognostic indicators in
mucoepidermoid carcinoma of salivary glands. J Otolaryngol.
32:328–331. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shemirani N, Osipov V, Kolker A, Khampang
P and Kerschner JE: Expression of mucin (MUC) genes in
mucoepidermoid carcinoma. Laryngoscope. 121:167–170. 2011.
View Article : Google Scholar : PubMed/NCBI
|
